tiprankstipranks
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
ASX:IMR
Australian Market
Want to see AU:IMR full AI Analyst Report?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Price & Analysis

10 Followers

IMR Stock Chart & Stats

AU$1.64
--
Market closed
AU$1.64
--

Bulls Say, Bears Say

Bulls Say
Niche MRI-compatible EP Product PortfolioImricor's focus on MRI-compatible electrophysiology systems targets a clear niche: MRI-guided cardiac ablation versus traditional X-ray. This specialization creates a durable technical differentiation and potential regulatory/clinical adoption advantages that can sustain long-term market positioning if clinical benefits drive standard of care shifts.
Balance-sheet Improvement (equity Turned Positive)The shift to positive equity is a meaningful structural improvement that reduces immediate insolvency risk and improves lender/investor confidence. Over a multi-month horizon, positive equity helps preserve access to capital markets and reduces near-term restructuring risk while the company pursues commercialization.
Improving Free Cash Flow TrendA reduction in negative free cash flow indicates early progress toward operational efficiency or scaled spending, extending runway and lowering the quantum of additional financing required. If sustained, this trend materially improves the company's ability to invest in commercialization and reduces dependence on dilutive funding.
Bears Say
Collapsing Revenue And Negative Gross ProfitA sharp, persistent revenue decline and recurring negative gross profit indicate fundamental demand or unit-cost problems. Over the medium term this undermines scale economics, impedes margin recovery, and forces reliance on external funding rather than operating cash generation to sustain product development and commercialization.
Consistent Heavy Cash BurnPersistent large operating and free cash outflows represent a durable financing pressure: recurring negative cash generation requires frequent capital raises, increases dilution risk, and constrains long-term investments in sales and R&D. Without sustained cash-flow improvement, strategic flexibility remains limited.
Elevated Leverage And Refinancing RiskHigh debt relative to equity increases refinancing and interest-rate vulnerability, especially given ongoing losses. Over the coming months this elevates the risk of covenant stress or costly refinancing, forcing trade-offs between dilution, asset sales, or cutting strategic investments to preserve liquidity.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh News

IMR FAQ

What was Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price range in the past 12 months?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh lowest share price was AU$1.15 and its highest was AU$2.25 in the past 12 months.
    What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap?
    Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap is AU$558.45M.
      When is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date?
      Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date is Sep 01, 2026 which is in 90 days.
        How were Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s earnings last quarter?
        Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, beating the consensus estimate of -AU$0.032 by AU$0.032.
          Is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh overvalued?
          According to Wall Street analysts Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pay dividends?
            Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh does not currently pay dividends.
            What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate?
            Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate is 0.
              How many shares outstanding does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh have?
              Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 320,947,020 shares outstanding.
                What happened to Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price movement after its last earnings report?
                Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh reported an EPS of AU$0 in its last earnings report, beating expectations of -AU$0.032. Following the earnings report the stock price went up 1.508%.
                  Which hedge fund is a major shareholder of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh?
                  Currently, no hedge funds are holding shares in AU:IMR
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Stock Smart Score

                    Company Description

                    Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

                    Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.

                    Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Earnings & Revenues

                    IMR Stock 12 Month Forecast

                    Average Price Target

                    AU$2.78
                    ▲(69.51% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","2":"AU$2","3":"AU$3","4":"AU$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$3.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$2.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$2.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.765,1.8946153846153846,2.024230769230769,2.1538461538461537,2.2834615384615384,2.413076923076923,2.542692307692308,2.672307692307692,2.801923076923077,2.9315384615384614,3.0611538461538466,3.190769230769231,3.3203846153846155,{"y":3.45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.765,1.843076923076923,1.921153846153846,1.9992307692307691,2.0773076923076923,2.155384615384615,2.233461538461538,2.3115384615384613,2.3896153846153845,2.4676923076923076,2.5457692307692303,2.623846153846154,2.7019230769230766,{"y":2.78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.765,1.8046153846153845,1.8442307692307691,1.8838461538461537,1.9234615384615383,1.963076923076923,2.0026923076923078,2.042307692307692,2.0819230769230765,2.1215384615384614,2.161153846153846,2.2007692307692306,2.240384615384615,{"y":2.28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.425,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.975,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.765,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Impedimed Limited
                    HeraMED Ltd.
                    Cyclopharm Limited
                    Micro-X Ltd.
                    EMvision Medical Devices Ltd.

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks